Tabrecta User Reviews & Ratings
Tabrecta has an average rating of 8.0 out of 10 from a total of 1 reviews on Drugs.com. 100% of reviewers reported a positive experience, while 0% reported a negative experience.
| Condition | Avg. Rating | Reviews | Compare |
|---|---|---|---|
| Non Small Cell Lung Cancer | 1 reviews for Non Small Cell Lung Cancer | 64 medications |
Are you taking this medicine?
Your review helps others make informed decisions.Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.
More about Tabrecta (capmatinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
For Non Small Cell Lung Cancer "Tolerated treatment well, and lung tumors decreased significantly in size after 3 months and did not progress after 6 months. The main side effect was swelling (edema) in feet and ankles."